Huiyu Pharmaceutical announced that the company participated in the 12th batch of centralized procurement tenders for national pharmaceuticals. The three products are to win the bid, namely injectable epizorubicin hydrochloride, injectable tecoranine, and calcium folinate injections. The procurement period is until December 31, 2029. Before winning the bid, the three products had generated sales revenue of 35.1844 million yuan, 1,332,400 yuan, and 246,400 yuan respectively. If a procurement contract is signed and implemented later, product sales will be expanded and performance will be improved. However, due to the normalization of collection, follow-up matters and the impact on performance are uncertain.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.